Skip to main content
. 2020 Nov 20;9(11):2514. doi: 10.3390/cells9112514

Figure 1.

Figure 1

Association of plasma KRAS G12/G13 mutation status with prognosis in NSCLC patients. Kaplan–Meier survival curves of (A) progression-free survival (PFS) and (B) overall survival (OS) based on KRAS G12/G13 mutation status in plasma. p values were calculated via the log-rank algorithm. The median PFS of patients with KRAS G12/G13-mutant cfDNA was 2.93 months as compared to 5.98 months for patients in the KRAS G12/G13-wild type cfDNA group (p < 0.001). The median OS duration for patients with KRAS G12/G13 mutations in plasma was 4.87 months versus 14.50 months for KRAS G12/G13-wild type plasma group (p < 0.001).